GILD jumps 27.2% in six months as FDA nod for twice-yearly HIV drug Yeztugo boosts its HIV franchise and growth outlook.

The Food and Drug Administration (FDA) recently approved lenacapavir for HIV prevention in both men and women. Many experts believe this twice a year treatment could be a game changer in the fight ...

Gilead Sciences, in partnership with the Global Fund, plans to supply a long-acting HIV prevention drug to low-income ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company ...

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...

Lenacapavir, the first FDA-approved, twice-yearly injectable PrEP for HIV prevention, shows 96% efficacy and offers ...

On Wednesday, the U.S. Food and Drug Administration (FDA) approved lenacapavir, a long-acting injection that was shown to be nearly 100% effective in clinical trials.

Analysts at RBC Capital Markets have predicted twice-yearly lenacapavir could become a $2 billion product, and become a key component of Gilead's PrEP franchise as it tries to ward off a challenge ...

The studies showed that two injections of lenacapavir respectively provided 100% protection against HIV infection in women and adolescent girls in South Africa and Uganda, and near-complete (99.9% ...

Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to ...